nicotinoyl-GABA: used in treatment of migraine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 60608 |
| CHEMBL ID | 4303255 |
| SCHEMBL ID | 678984 |
| MeSH ID | M0130869 |
| Synonym |
|---|
| 34562-97-5 |
| AC-19324 |
| BB 0258436 |
| pikamilone |
| picamilon |
| CBKINASE1_003003 |
| EU-0052131 |
| CBKINASE1_015403 |
| gaba-ng |
| pikamilon |
| butanoic acid, 4-((3-pyridinylcarbonyl)amino)- |
| nicotinoyl-gaba |
| 4-(pyridine-3-carbonylamino)butanoic acid |
| STK760083 |
| AKOS000126425 |
| n-(3-carboxypropyl)nicotinamide |
| 4-[(pyridin-3-ylcarbonyl)amino]butanoic acid |
| 4-(pyridine-3-carbonylamino)butanoic acid;pikamilone |
| A822275 |
| 0s5n9sek4n , |
| unii-0s5n9sek4n |
| FT-0639198 |
| 4-(nicotinamido)butanoic acid |
| 3-[(3-carboxypropyl)carbamoyl]pyridine |
| S5363 |
| n-nicotinoyl-gamma-aminobutyric acid |
| 4[(pyridine-3-carbonyl)-amino]-butyric acid |
| NAJVRARAUNYNDX-UHFFFAOYSA-N |
| SCHEMBL678984 |
| mfcd00186518 |
| 4-nicotinoylamino-butyric acid |
| 4-[(pyridine-3-carbonyl)amino]butyric acid |
| pycamilon |
| pikatropin |
| nicotinoyl-.gamma.-aminobutyric acid |
| W-202413 |
| N0998 |
| 4-(nicotinamido)butyric acid |
| n-nicotinoyl-gaba |
| sr-01000523993 |
| butanoic acid, 4-[(3-pyridinylcarbonyl)amino]- |
| DTXSID40188098 |
| 4-[(pyridin-3-yl)formamido]butanoic acid |
| AC-33105 |
| 1h-pyrazole, 1-(2-methylpropyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- |
| 4-[(3-pyridinylcarbonyl)amino]butanoic acid |
| Z235541930 |
| SR-01000523993-1 |
| 3-((3-carboxypropyl)carbamoyl)pyridine |
| BCP19066 |
| Q4362563 |
| AS-14847 |
| HMS3886A04 |
| CCG-266641 |
| CHEMBL4303255 |
| nicotinoyl-gaba; nicotinoyl-gamma-aminobutyric acid |
| nicotinoyl-gaba (sodium); nicotinoyl-gamma-aminobutyric acid (sodium) |
| pikamilone (sodium) |
| D70208 |
| nicotinoyl-gaba; nicotinoyl--aminobutyric acid |
| EN300-113400 |
| nicotinoyl-gaba (sodium); nicotinoyl--aminobutyric acid (sodium) |
| SB77795 |
| CS-0028604 |
| SY050468 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Electric impedance measurements on awake rabbits with electrodes implanted into cortex, thalamus, and hypothalamus showed that modeling of the noise and general (wide-band) vibration, as well as their combination with sea-sickness action, leads to disturbances in the aqueous-electrolyte balance in brain." | ( [Effects of pikamilon on the brain water-electrolyte balance and in models of responses to the noise and vibration exposure, and their combination with motion sickness]. Sapegin, ID, ) | 0.13 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The drug bioavailability at oral administration to mice is 21." | ( [Pikamilon pharmacokinetics in animals]. Dorofeev, BF; Kholodov, LE, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.90) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (10.53%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 34 (89.47%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||